anti-egfr immunoliposomes loaded with doxorubicin
mAbexperimentalADC
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT01702129)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- doxorubicin
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-egfr immunoliposomes loaded with doxorubicin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02833766 | Phase 2 | Oct 1, 2016 | Luzerner Kantonsspital, Swiss Group for Clinical Cancer Research |
| NCT01702129 | Phase 1 | Jan 1, 2007 | Kantonsspital Aarau, University of Bern |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kantonsspital Aarau | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Luzerner Kantonsspital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Swiss Group for Clinical Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2007 |
4 organizations
Page 1 / 1